Clinical Trial: Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Anderogenetic Alopecia

ProQuest document link

FULL TEXT

U.S., Feb. 2 -- ClinicalTrials.gov registry received information related to the study (NCT06239207) titled 'Efficacy and Safety of Exosomes Versus Platelet Rich Plasma in Patients of Anderogenetic Alopecia' on Jan. 25.

Brief Summary: Androgenetic alopecia is a common condition affects both genders. Patients of androgenetic alopecia following inclusion criteria will be enrolled after ethical approval and informed consent. Pre-treatment assessment will be done by hair pull test, global physican assessment, patient global assessment and hair density by trichoscopy of areas under treatment. Patients will be categorized in 2 groups. Group A receiving exosomes 1session intradermally in scalp after nerve block and group B receiving PRP 2 sessions 1 month apart intradermally in scalp after nerve block. Patients will receive exosomes at strength of 2 to 10 billion particles/5ml with 0.1 ml/cm2. Follow up will be done after 1 month, 2 months, 3 months, 5 months and 6 months of completion of treatment to assess hair growth and hair fall by GPA and trichography. Clinical response will be graded as satisfactory (50%) improvement. Details will be entered on predesigned proforma. Data will be entered and analyzed using SPSS 27. Means will be calculated for quantitative variables, frequencies for qualitative variables like pre- and post treatment response. Data will be stratified for role of effect modifiers

Study Type: Interventional

Condition: Androgenetic Alopecia

Intervention: Drug: Exosomes GFC CELL EXO SCALP KIT (Leuco Exo 97%)

Exosomes used are GFC CELL consist of Leuco exo 97% having GFC CELL EXO SCALP 9700 powder and EXO SCALP

Pep9 solution

Other Name: platelet rich plasma

Recruitment Status: Active, Not Recruiting

DETAILS

Subject:	Baldness; Alopecia
Publication title:	US Fed News Service, Including US State News; Washington, D.C.
Publication year:	2024
Publication date:	Feb 2, 2024
Publisher:	HT Digital Streams Limited
Place of publication:	Washington, D.C.



Country of publication: India Publication subject: Public Administration Source type: Wire Feed Language of publication: English Document type: News ProQuest document ID: 2921320412 Document URL: https://www.proquest.com/wire-feeds/clinical-trial-efficacy-safety-exosomesversus/docview/2921320412/se-2?accountid=14723 Copyright: Copyright HT Digital Streams Limited Feb 2, 2024 Last updated: 2024-02-03 Database: Research Library

LINKS

Get it at UQ Library

Database copyright © 2025 ProQuest LLC. All rights reserved.

Terms and Conditions Contact ProQuest

